SGCB and pulmonary arterial hypertension: In fact, at least four drug approvals further strengthened this link: (1) the PDE5 inhibitors for erectile dysfunction and pulmonary arterial hypertension (PAH); (2) the first sGC stimulator in class, riociguat, in pulmonary arterial hypertension; (3) more recently the neprylisin inhibitor sacubitril combined with valsartan as well as (4) the sGC stimulator vericiguat in chronic heart failure (HF).